Sirvi Märksõna "5xFAD" järgi
Nüüd näidatakse 1 - 2 2
- Tulemused lehekülje kohta
- Sorteerimisvalikud
listelement.badge.dso-type Kirje , listelement.badge.access-status Avatud juurdepääs , A preclinical trial of Bisdemethoxycurcumin in a mouse model of Alzheimer's disease(Tartu Ülikool, 2022) Mansouri, Seyedeh Elnaz Sadat; Tartu Ülikool. Loodus- ja täppisteaduste valdkond; Tartu Ülikool. Tehnoloogiainstituutlistelement.badge.dso-type Kirje , listelement.badge.access-status Avatud juurdepääs , Selecting endpoints to use in preclinical trials in a mouse model of Alzheimer’s disease(Tartu Ülikool, 2021) Aid, Jana; Tõnissoo, Tambet, juhendaja; Hickey, Miriam Ann, juhendaja; Tartu Ülikool. Loodus- ja täppisteaduste valdkond; Tartu Ülikool. Molekulaar- ja rakubioloogia instituutAlzheimer’s disease (AD) is a neurodegenerative disorder of the brain, that leads to cognitive impairment. AD is characterised by the accumulation of β-amyloid peptides and tau proteins into amyloid plaques and neurofibrillary tangles. AD currently has no cure, however promising research and treatment is underway. The aim of this work is to determine appropriate endpoints to use in a preclinical trial of 5xFAD mouse model of AD. In this thesis, I demonstrate endpoints appropriate to use for preclinical trials and appropriate group and effect sizes.